A30-minute, near-patient test for diseases such as meningitis and the superbug MRSA has taken a step towards development, thanks to a £400,000 boost.
Boost for nearpatient testing
The technology pioneer, Atlas Genetics, is currently developing portable technology that will detect the presence of DNA from the disease pathogen in a patient’s blood, urine or saliva sample. When developed, the technology will enable hospitals and GPs to make a diagnosis within 30 minutes. The funding, which will be used to take the technology to first prototype stage, comes from partners such as the South West Ventures Fund, private investors such as the South West Angel and Investor Network and the Great Eastern Investment Forum.
